Amx0035 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04516096 (ClinicalTrials.gov) | November 22, 2020 | 9/8/2020 | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | AMX0035 for Amyotrophic Lateral Sclerosis - Compassionate Use Protocol | Amyotrophic Lateral Sclerosis | Drug: AMX0035 | Amylyx Pharmaceuticals Inc. | NULL | Enrolling by invitation | 18 Years | N/A | All | 40 | Phase 2;Phase 3 | United States |
| 2 | NCT03488524 (ClinicalTrials.gov) | March 29, 2018 | 23/3/2018 | Open Label Extension Study of AMX0035 in Patients With ALS | Open Label Extension Study of AMX0035 in Patients With ALS | Amyotrophic Lateral Sclerosis;ALS | Drug: AMX0035 | Amylyx Pharmaceuticals Inc. | Massachusetts General Hospital Neurology Clinical Research Institute | Enrolling by invitation | N/A | N/A | All | 132 | Phase 2 | United States |
| 3 | NCT03127514 (ClinicalTrials.gov) | June 22, 2017 | 12/4/2017 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS | Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Diseases;Neurodegenerative Diseases;Spinal Cord Diseases;TDP-43 Proteinopathies;Nervous System Diseases;Central Nervous System Diseases | Drug: AMX0035;Other: Placebo | Amylyx Pharmaceuticals Inc. | ALS Finding a Cure Foundation;ALS Association;Northeast ALS Consortium;Massachusetts General Hospital Neurology Clinical Research Institute;Leandro P. Rizzuto Foundation | Completed | 18 Years | 80 Years | All | 137 | Phase 2;Phase 3 | United States |